Mueller Jennifer J, Holzapfel Marie, Han Chan H, Santos Kevin, Gunderson Camille, Moore Kathleen, Erickson Britt, Leath Charles A, Diaz Elena, Walsh Christine, Wethington Stephanie L, Dejbakhsh Sheila Z, Barakat Richard R, Gardner Ginger J, Hyman David M, Soslow Robert A, Leitao Mario M
*Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; †Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; ‡University of Oklahoma Health Sciences Center, Oklahoma City, OK; §Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL; ∥Department of Obstetrics and Gynecology, Weill Cornell Medical Center, New York, NY; ¶Department of Medicine, Weill Cornell Medical Center, New York, NY; #Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; and **Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY.
Int J Gynecol Cancer. 2016 Jan;26(1):120-4. doi: 10.1097/IGC.0000000000000559.
The purpose of this study was to assess the rate of lymph node (LN) metastasis in comprehensively staged ovarian clear cell carcinoma (OCCC) clinically confined to the ovary and determine factors associated with LN metastasis.
We identified all cases of OCCC treated at 4 institutions from January 1994 through December 2011. We included cases with disease grossly confined to the ovary that had surgical staging performed, including at least 10 LNs sampled. Clinical and pathologic data were abstracted from electronic medical records, and a deidentified data set was compiled and processed at a single institution. Factors potentially associated with LN metastasis were tested. Appropriate statistical tests were performed.
We identified 145 eligible cases that met the criteria for this analysis. Median age was 52.9 years (range, 30-81 years), and median total LN count was 19 (range, 10-74). Seven (4.8%) of 145 comprehensively staged cases had LN metastasis; 6 of these cases (4.1%) were isolated metastasis. Cytologic washings, peritoneal, omental, and fallopian tube involvement were not associated with nodal metastasis. Cases with ovarian surface involvement and positive cytology had a 37.5% incidence of LN positivity, which was statistically meaningful when compared with all other cases (P = 0.003).
Women who underwent comprehensive staging for clinical stage I OCCC had an LN metastasis rate of 4.8%. The subgroup of cases with both ovarian surface involvement and positive cytology had the highest incidence of LN metastasis. This may influence clinical decision making on whether to perform lymphadenectomy in patients with incidental OCCC found after salpingo-oophorectomy.
本研究旨在评估临床局限于卵巢的综合分期卵巢透明细胞癌(OCCC)的淋巴结(LN)转移率,并确定与LN转移相关的因素。
我们确定了1994年1月至2011年12月在4家机构接受治疗的所有OCCC病例。我们纳入了疾病大体局限于卵巢且进行了手术分期的病例,包括至少采集了10个LN样本。从电子病历中提取临床和病理数据,并在单一机构汇编和处理去识别化的数据集。对可能与LN转移相关的因素进行了测试。进行了适当的统计检验。
我们确定了145例符合本分析标准的合格病例。中位年龄为52.9岁(范围30 - 81岁),中位LN总数为19个(范围10 - 74个)。145例综合分期病例中有7例(4.8%)发生LN转移;其中6例(4.1%)为孤立转移。细胞学冲洗液、腹膜、网膜和输卵管受累与淋巴结转移无关。卵巢表面受累且细胞学阳性的病例LN阳性发生率为37.5%,与所有其他病例相比具有统计学意义(P = 0.003)。
接受临床I期OCCC综合分期的女性LN转移率为4.8%。卵巢表面受累且细胞学阳性的病例亚组LN转移发生率最高。这可能会影响对输卵管卵巢切除术后偶然发现的OCCC患者是否进行淋巴结清扫术的临床决策。